ASTH is now overvalued and could go down -25%

Based on our analysis, Apollo Medical Holdings has received an overvalued rating of 2 out of 5 stars from Cashu. Several key financial ratios indicate potential concerns for investors. The company's Price-to-Earnings (PE) Ratio stands at 33.19, significantly higher than the sector average of 14.18. A high PE ratio suggests that the stock may be overvalued relative to its earnings, which could deter potential investors looking for value opportunities. Moreover, Apollo Medical's Dividend Yield is 0.81, lower than the sector's average of 1.18. A lower dividend yield may indicate that the company is not returning as much value to shareholders in the form of dividends compared to its peers, which can be a red flag for income-focused investors. In addition, the company's Return on Assets (ROA) is 3.18, while the sector average is notably negative at -47.59. Although Apollo Medical's ROA is positive, it is considerably lower than the sector, suggesting that the company may not be as efficient in generating profit from its assets. These financial metrics highlight areas where Apollo Medical Holdings does not outperform its sector, contributing to its overvalued assessment. Investors should consider these factors when evaluating the company’s market position. This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.